Relapsed hydroxychloroquine induced thrombocytopenia in a systemic lupus erythematosus patient.
Hydroxychloroquine is used in the long-term therapy of systemic lupus erythematosus (SLE). Although considered to be a safe treatment, side effects have been documented. An uncommon side effect is thrombocytopenia. In order to establish the diagnosis of thrombocytopenia secondary to Hydroxychloroquine, non-pharmacological causes must be ruled out and it is necessary to determine a recurrence after re-exposure to the drug. We present one case of severe thrombocytopenia occurring in a patient with SLE undergoing treatment with Hydroxychloroquine.
Servicio de Medicina Interna, Hospital Moisès Broggi, Sant Joan Despí Barcelona, Barcelona, España. Electronic address: vanesa.anton.v@gmail.com.
Vanesa
V
Antón Vázquez
Servicio de Medicina Interna, Hospital Moisès Broggi, Sant Joan Despí Barcelona, Barcelona, España.
Luis
L
Pascual
Servicio de Reumatología, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, España.
Héctor
H
Corominas
Servicio de Nefrología, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, España.
Isabel
I
Giménez Torrecilla
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects* / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis
D018501:Antirheumatic Agents; D006886:Hydroxychloroquine
Hidroxicloroquina; Hydroxychloroquine; Lupus eritematoso sistémico; Systemic lupus erythematosus; Thrombocytopenia; Trombocitopenia